Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors

NCT04526106 is registered in ClinicalTrials.gov with Elevar Therapeutics as lead sponsor.

NCT NCT04526106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04526106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
Lead sponsor
Elevar Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
September 2, 2020
Completion date
September 5, 2025
Enrollment
490 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, fgfr2 amplification, fgfr2 gene activation, fgfr2 gene fusion/rearrangement, fgfr2 gene mutation, fgfr2 gene translocation, intrahepatic cholangiocarcinoma, other solid tumors, adult